SugeMalimab after lung radiation and chemotherapy for limited-stage SCLC
Treatments studied
Part of Cancer clinical trials.
This trial tests sugemalimab as “extra treatment” after standard chemoradiation for limited-stage small cell lung cancer. It aims to lower the chance of the cancer coming back by helping the immune system stay active after initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have small cell lung cancer confirmed by lab testing of tumor cells or tissue
- Your cancer is limited-stage (stages I to III) and can be treated with planned curative-strength radiation
- You cannot (or choose not to) have surgery, or surgery is not safe for you
- You completed 4 cycles of chemotherapy (etoposide plus carboplatin or cisplatin) with radiation during the first 2 cycles, on an approved timing schedule
- After chemoradiation, the cancer has not worsened (response can be complete response, partial response, or stable disease)
- You can provide tumor samples for genetic testing and agree to birth control rules if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
This trial tests a cancer-fighting antibody (sugemalimab) added to standard chemotherapy for stage III lung cancer that can’t be removed by surgery but may be treated with radiation. It aims to improve control of your cancer while checking safety and side effects.
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.